Tag: Axovant Sciences
Axovant Sciences Announces Pricing of $40 Million Public Offering of Common Shares
Axovant Sciences (NASDAQ:AXGT) has announced the pricing of its underwritten public offering of 26.6 million of its common shares at...
Axovant Sciences (Nasdaq:AXON) announced the pricing of its underwritten public offering of 30,000,000 of its common shares at a price...
Axovant Doses First Patient in Parkinson's Trial
The drug, AXO-Lenti-PD, was well tolerated and the patient was able to leave the hospital as expected with no side...
Axovant Announces Dosing of First Patient in Clinical Study of AXO-Lenti-PD
Axovant Sciences (NASDAQ:AXON), a company developing innovative gene therapies for neurologic and neuromuscular diseases, announced dosing of the first patient...
Axovant Announces Global Licensing Agreement for AXO-AAV-OPMD
Axovant Sciences (NASDAQ:AXON) today announced that it has licensed exclusive global rights to an investigational Silence-and-Replace gene therapy program from...
Axovant Licenses Investigational Gene Therapy for Parkinson's Disease from Oxford BioMedica and Announces Key Leadership Team Addition
Axovant Sciences (NASDAQ:AXON) announced that it has licensed the exclusive worldwide rights to develop and commercialize OXB-102, now AXO-Lenti-PD, from...